A new MAP-Rasagiline conjugate reduces α-synuclein inclusion formation in a cell model
- 7 Downloads
Parkinson’s disease (PD) is the second most common neurodegenerative disease of the elderly. Current therapies are only symptomatic, and have no disease-modifying effect. Therefore, disease progresses continuously over time, presenting with both motor and non-motor features. The precise molecular basis for PD is still elusive, but the aggregation of the protein alpha-synuclein (α-syn) is a key pathological hallmark of the disease and is, therefore, a major focus of current research. Considering the intrinsic properties of cell-penetrating peptides (CPPs) for mediating drug delivery of neurotherapeutics across the blood brain barrier (BBB), these might open novel opportunities for the development of new solutions for the treatment of brain-related aspects of PD and other neurodegenerative disorders.
Here, we synthesized solid-phase CPPs using an amphipathic model peptide (MAP) conjugated with the drug Rasagiline (RAS), which we named RAS-MAP, and evaluated its effect on α-syn inclusion formation in a human cell-based model of synucleinopathy.
We found that treatment with RAS-MAP at low concentrations (1–3 µM) reduced α-syn aggregation in cells.
For the first time, we report that conjugation of a current drug used in the therapy of PD with CPP reduces α-syn aggregation, which might prove beneficial in PD and other synucleinopathies.
KeywordsAlpha-synuclein Cell-penetrating peptides Lewy bodies Parkinson’s disease Rasagiline
Blood brain barrier
Central nervous system
High-pressure liquid chromatography
Monoamide oxidase B
Amphipathic model peptide
Reverse-phase medium-pressure liquid chromatography
TVP-1012 in early monotherapy for PD outpatients
Attenuation of disease progression with Azilect given once—daily
Parkinson’s Rasagiline: efficacy and safety in the treatment of “Off”
Lasting effect in adjunct therapy with Rasagiline given once—daily
This work was financed by FEDER—Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020—Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT, in the framework of the project “Institute for Research and Innovation in Health Sciences” (POCI-01-0145-FEDER-007274), and through project IF/00092/2014/CP1255/CT0004. SS thanks her PhD Grant (PD/BD/135456/2017) from FCT. NV thanks FCT by IF position, Fundação Manuel António da Mota (FMAM, Portugal) and Pfizer Portugal by support Nuno Vale Lab. NV and PG thank Dr. Marco Colombo, from Dipharma, for the supply of Rasagiline used in the first phase of the work. The contents of this report are solely the responsibility of the authors and do not necessarily represent the official views of the FCT, FMAM or Pfizer Portugal. TFO was supported by the DFG Center for Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB).
This work has been financed by the Portuguese founds from Fundação para a Ciência e a Tecnologia (FCT), through of Grant Number IF/00092/2014/CP1255/CT0004.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interests.
- 12.Chung CY, Koprich JB, Siddiqi H, Isacson O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV-synucleinopathy. J Neurosci. 2009;29:3365–73. https://doi.org/10.1523/JNEUROSCI.5427-08.2009.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, et al. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson’s disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol. 2000;23:324–30. https://doi.org/10.1097/00002826-200011000-00005.CrossRefPubMedGoogle Scholar
- 34.Oehlke J, Scheller A, Wiesner B, Krause E, Beyermann M, Klauschenz E, et al. Cellular uptake of an α-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim Biophys Acta Biomembr. 1998;1414:127–39. https://doi.org/10.1016/S0005-2736(98)00161-8.CrossRefGoogle Scholar
- 35.Oehlke J, Wallukat G, Wolf Y, Ehrlich A, Wiesner B, Berger H, et al. Enhancement of intracellular concentration and biological activity of PNA after conjugation with a cell-penetrating synthetic model peptide. Eur J Biochem. 2004;271:3043–9. https://doi.org/10.1111/j.1432-1033.2004.04236.x.CrossRefPubMedGoogle Scholar
- 38.Nagel F, Falkenburger BH, Tönges L, Kowsky S, Pöppelmeyer C, Schulz JB, et al. Tat-Hsp70 protects dopaminergic neurons in midbrain cultures and in the substantia nigra in models of Parkinson’s disease. J Neurochem. 2008;105:853–64. https://doi.org/10.1111/j.1471-4159.2007.05204.x.CrossRefPubMedGoogle Scholar
- 41.Lázaro DF, Rodrigues EF, Langohr R, Shahpasandzadeh H, Ribeiro T, Guerreiro P, et al. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. PLoS Genet. 2014;10(11):e1004741. https://doi.org/10.1371/journal.pgen.1004741.CrossRefPubMedPubMedCentralGoogle Scholar